Breastlink Research Group has a long history of working with research entities searching for new and better treatment options. While we cannot publish a complete list of breast cancer clinical trials we have been apart of, we hope the list found below is helpful to our current and future patients.

If you are interested in more information about our clinical trials program(s) contact our research group at (562) 981-6101.

Clinical Trials Currently Recruiting Participants (as of March 2015):

A Study of Neoadjuvant Letrozole + GDC-0032 Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI).

  • Sponsor: Genentech, Inc.
  • Identifier: NCT02273973

A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients With HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE).

  • Sponsor: Hoffmann-La Roche
  • Collaborator(s): German Breast Group and National Surgical Adjuvant Breast and Bowel Project (NSABP)
  • Clinical Identifier: NCT01772472

A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer. (KAITLIN)

  • Sponsor: Hoffmann-La Roche
  • Identifier: NCT01966471

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting.

  • Sponsor: Puma Biotechnology, Inc.
  • Identifier: NCT01808573

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

  • Sponsor: AbbVie
  • Identifier: NCT02163694

A Safety and Efficacy Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft® Axxent® eBx™ System at the Time of Breast Conservation Surgery for Early Stage Breast Cancer.

  • Sponsor: XOFT, Inc.
  • Collaborator: Icad, Inc.
  • Identifier: NCT01644669

Prospective Neo-adjuvant REGISTRY Trial Linking MammaPrint, Subtyping and Treatment Response: Neoadjuvant Breast Registry – Symphony Trial (NBRST).

  • Sponsor: Agendia
  • Identifier: NCT01479101

Cryoablation of Low Risk Breast Cancer Less Than 1.5 cm: An Evaluation of Local Recurrence (Ice3 Trial)

  • IceCure Medical Ltd.
  • Identifier: NCT02200705

Caris Biorepository Research Protocol

  • Sponsor: Caris Science, Inc.
  • Identifier: NCT01499394

PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score

  • Sponsor: Agendia
  • Identifier: NCT01617954

Clinical Studies that are On-going, not Recruiting Participants (March 2015):

An Open-label, Phase II, Single-arm Study of Everolimus in Combination With Letrozole in the Treatment of Postmenopausal Women With Estrogen Receptor Positive HER2 Negative Metastatic or Locally Advanced Breast Cancer.

  • Sponsor: Novartis Pharmaceuticals
  • Identifier: NCT01698918

Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer.

  • Sponsor: Southwest Oncology Group
  • Collaborator: National Cancer Institute (NCI)
  • Identifier: NCT01097278

A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy.

  • Sponsor: National Cancer Institute (NCI)
  • Identifier: NCT00769379

A Pivotal Study of Imaging With Opto-acoustics to Diagnose Breast Masses Detected by Mammography and/or Diagnostic Ultrasound: A New Evaluation Tool for Radiologists. (SENO-PIONEER-01).

  • Sponsor: Seno Medical Instruments Inc.
  • Identifier: NCT01943916

A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids.

  • Sponsor: AbbVie
  • Identifier: NCT01817530

Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer.

  • Sponsor: American College of Surgeons.
  • Collaborators: National Cancer Institute (NCI) Cancer and Leukemia Group B.
  • Identifier: NCT00265759.

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer.

  • Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP).
  • Collaborators: National Cancer Institute (NCI) and Novartis.
  • Identifier: NCT00382070.

An Open-Label Study of Trastuzumab Emtansine (T-DM1) vs. Capecitabine+Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer (EMILIA).

  • Sponsor: Genentech.
  • Identifier: NCT00829166.

A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer.

  • Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP).
  • Collaborator: GlaxoSmithKline.
  • Identifier: NCT00486668.

Zoledronate, Clodronate, or Ibandronate in Treating Women Who Have Undergone Surgery for Stage I, Stage II, or Stage III Breast Cancer.

  • Sponsor: Southwest Oncology Group.
  • Collaborators: National Cancer Institute (NCI), North Central Cancer Treatment Group, Eastern Cooperative Oncology Group, National Surgical Adjuvant Breast and Bowel Project (NSABP), Cancer and Leukemia Group B and NCIC Clinical Trials Group.
  • Identifier: NCT00127205.

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Of Fulvestrant (Faslodex) With Or Without PD-0332991 (Palbociclib) +/- Goserelin In Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy

  • Sponsor: Pfizer
  • Collaborator: AstraZeneca
  • Identifier: NCT01942135


Recently completed trials (not a complete list).

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer (ExteNET).

  • Sponsor: Puma Biotechnology, Inc.
  • Identifier: NCT00878709.

For more information please visit